Minocycline/disodium edetate/ethyl alcohol

Drug Profile

Minocycline/disodium edetate/ethyl alcohol

Alternative Names: HEAL solution; Mino-Lok Therapy (MLT); Mino-Lok™; Minocycline-EDTA-EtOH

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Class Anti-infectives; Anticoagulants
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Catheter infections

Most Recent Events

  • 23 Mar 2017 Citius Pharmaceuticals acquires license for minocycline/disodium edetate/ethyl alcohol in South America
  • 19 Dec 2016 Citius Pharmaceuticals submits drug master file to the US FDA
  • 19 Sep 2016 Citius Pharma announces intention to submit NDA to US FDA (Citius Pharma pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top